Key Takeaways
- Diagnostics Rally: Caris Life Sciences stock jumped 9% Tuesday as diagnostics peers rallied together.
- Street Split: Nine buys, one outperform and four holds now cover Caris Life Sciences stock, and the $28 mean target sits 3% below Tuesday’s close, a reversal from the 83% premium targets carried six months ago.
- Model Gap: TIKR’s valuation model puts Caris Life Sciences stock’s fair value at $110, implying 285% total return and 37% annualized over the next 4.3 years.
- Whale Stake: Amundi disclosed a 5,709.5% jump in its Caris Life Sciences holding just three days before the rally, even as a $100 million buyback and President David Spetzler’s tax-related share sale continued in the background.
Why Caris Life Sciences Stock Jumped 9% in a Diagnostics-Wide Rally
Caris Life Sciences (CAI) stock climbed 9% on Tuesday, September 15, closing at $29 as a rally in precision-oncology diagnostics lifted Illumina, Tempus AI and Quest Diagnostics right alongside it. Caris Life Sciences stock built momentum through the session and finished sharply higher.
That divergence matters. The broader market, and the healthcare sector benchmark XLV, closed lower that day as Treasury yields pushed above 5% and oil traded near $105 a barrel ahead of the Federal Reserve’s rate decision. Caris Life Sciences stock rallying against that tape points to buying specific to the diagnostics group, not a market-wide bounce, and no single earnings print or regulatory decision explains why Illumina and Tempus AI moved the same day. The cleaner read is capital rotating into precision oncology as a group, with Caris Life Sciences stock the biggest beneficiary.
Two concrete threads fed the rally beyond the sector move. Amundi disclosed a 5,709.5% increase in its Caris Life Sciences stake in a 13F filing, a mandatory disclosure of institutional stock holdings, buying 1,197,392 additional shares to bring its position to 1,218,364 shares worth $21.7 million, or roughly 0.43% of the company. The company’s $100 million share buyback, authorized in June and covering up to 2.1% of shares outstanding, has also stayed active in the market, and Caris Life Sciences spent part of September on an investor roadshow that included a stop at the Morgan Stanley healthcare conference.
Insider selling didn’t slow the buying. President David Spetzler sold 478,000 shares on September 3 at an average price of $25, about $11.9 million, in a Form 4 filing that described the sale as covering tax withholding on vested equity awards. The trade cut his direct stake by 31%, to 1,052,083 shares, though insiders as a group still hold half the company, a base large enough that one executive’s tax sale barely dents the alignment story.
Wall Street’s own read stayed mixed through early September. Seven analysts rated Caris Life Sciences stock a buy, five held, and one called it a sell, for a consensus Hold and an average target near $27, and BTIG had only just raised its own target to $33 in early August while Wolfe Research had already cut its rating to peer perform back in June. That split explains why Tuesday’s jump looks less like Wall Street catching up and more like the market moving without it.
Caris Life Sciences stock is now trading on institutional conviction that has run ahead of the Street’s own targets, and that gap is the real story of this rally.
Caris Life Sciences Stock’s Rally Outpaces a Cautious Street
Nine analysts rate Caris Life Sciences stock a buy, one calls it an outperform, and four rate it a hold, the widest ratings split the stock has carried since its 2025 debut. The mean target sits at $28, roughly 3% below Tuesday’s close, putting the average Wall Street price target behind the stock for the first time in the table’s history.
That inversion is new. Coverage grew from 8 analysts at the end of September 2025 to 13 today, and the mean target fell from $39 to $28 over that stretch, even as the stock swung from $30 down to an $18 low and back to $29. The premium peaked at 83% above the close in March, when the stock traded near its low, and had narrowed to 56% by June. Now, after Tuesday’s jump, the price has caught up to the target and moved past it, even as the analyst count kept climbing instead of thinning out. Analysts are not chasing this rally. They are watching it happen.
TIKR Values Caris Life Sciences Stock at $110, a Path Far Beyond the Street
TIKR’s mid-case model values Caris Life Sciences stock at $110 by the end of 2030, implying a 285% total return from the current price of $29, or 37% annualized over the next 4.3 years.
A 37% annualized return sits well above what the market typically prices into an established diagnostics name, and it puts TIKR’s model far ahead of both the Street’s own $28 mean target and the price Caris Life Sciences stock already fetches after Tuesday’s jump.
The rally that pushed Caris Life Sciences stock through a falling market points to real institutional demand, not a one-day bounce, and that demand is arriving while the Street’s own numbers have not moved and coverage keeps expanding rather than shrinking. Closing the distance between a market re-rating the stock in real time and analysts still working off pre-rally targets, with a growing bench of thirteen analysts now watching for the next update, is exactly what TIKR’s model is pricing.
Should You Invest in Caris Life Sciences, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Caris Life Sciences, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Caris Life Sciences, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze CAI stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
